These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 7577479)

  • 1. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
    Archer SG; Eliopoulos A; Spandidos D; Barnes D; Ellis IO; Blamey RW; Nicholson RI; Robertson JF
    Br J Cancer; 1995 Nov; 72(5):1259-66. PubMed ID: 7577479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.
    Nicholson RI; McClelland RA; Gee JM; Manning DL; Cannon P; Robertson JF; Ellis IO; Blamey RW
    Breast Cancer Res Treat; 1994 Jan; 29(1):117-25. PubMed ID: 7912565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
    Leitzel K; Teramoto Y; Konrad K; Chinchilli VM; Volas G; Grossberg H; Harvey H; Demers L; Lipton A
    J Clin Oncol; 1995 May; 13(5):1129-35. PubMed ID: 7738618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
    Ferrero-Poüs M; Hacène K; Bouchet C; Le Doussal V; Tubiana-Hulin M; Spyratos F
    Clin Cancer Res; 2000 Dec; 6(12):4745-54. PubMed ID: 11156229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
    Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice.
    Mehta RR; Graves JM; Warso MA; Das Gupta TK
    Br J Cancer; 1995 Nov; 72(5):1160-4. PubMed ID: 7577462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
    Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
    J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.
    Nicholson RI; McClelland RA; Finlay P; Eaton CL; Gullick WJ; Dixon AR; Robertson JF; Ellis IO; Blamey RW
    Eur J Cancer; 1993; 29A(7):1018-23. PubMed ID: 8098946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between expression of c-ras, c-erbB-2, nm23, and p53 gene products and development of trophoblastic tumor and their predictive significance for the malignant transformation of complete hydatidiform mole.
    Yang X; Zhang Z; Jia C; Li J; Yin L; Jiang S
    Gynecol Oncol; 2002 Jun; 85(3):438-44. PubMed ID: 12051871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
    Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
    Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
    Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
    Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling.
    Tovey SM; Witton CJ; Bartlett JM; Stanton PD; Reeves JR; Cooke TG
    Breast Cancer Res; 2004; 6(3):R246-51. PubMed ID: 15084248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
    Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
    Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
    Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
    Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer.
    Pinto AE; André S; Laranjeira C; Soares J
    Pathology; 2005 Feb; 37(1):45-50. PubMed ID: 15875733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.